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Background
Chemotherapeutic drug clinical outcomes are genetically
determined as there is a large heterogeneity in the
response to, and toxicity of, chemotherapeutic agents in
breast cancer patients. Polymorphisms in genes encoding
Phase I – Cytochrome P450 (CYP450) and NAD(P)H
dehydrogenase quinine (NQO1); phase II - glutathione-
Stransferase (GST) and methylene tetra hydrofolate reduc-
tase (MTHFR); phase III- p-glycoprotein (ABCB1) and
solute transporter (SLC22A16) drug metabolizing enzymes
can possibly predict clinical outcomes, and can be of prog-
nostic significance in breast cancer patients. The aim of
this study was to determine the role of genetic variations
in drug metabolizing enzymes in predicting response and
toxicity in breast cancer patients, using multi-analytical
approaches.
Materials & methods
Two hundred and four North Indian cases of histology
proven invasive breast carcinoma treated at the our
institute were genotyped for 17 polymorphisms by Poly-
merase Chain Reaction (PCR) or PCR-Restriction Frag-
ment Length Polymorphism (RFLP) or Taqman allelic
discrimination assay. All patients were treated with
combination chemotherapy containing an anthracycline
drug—epirubicin (62.70 %) or doxorubicin (37.25%)
along with cyclophosphamide and 5-fluorouracil. Tumor
response to NACT was recorded in 96 patients accord-
ing to Response Evaluation Criteria in Solid Tumors
(RECIST). Toxicological data was recorded according
to National Cancer Institute- Common Terminology
Criteria for Adverse Events (NCI-CTCAE). The highest
grade toxicity that occurred in an individual patient dur-
ing the course of treatment was used for the analysis.
Genetic variations were correlated with response to
NACT and chemo-toxicity using logistic regression
through SPSS software, version 17.0. Furthermore,
higher-order gene-gene interactions were determined
through multifactor dimensionality reduction (MDR)
using software version 2.0 beta8.
Results
Heterozygous (CT) and variant (TT) genotype of ABCB1
1236C>T polymorphism was found to be significant with
breast cancer response to NACT. Similarly, heterozygous
(CT) genotype of ABCB1 1236C>T polymorphism was
significantly associated with grade 2-4 anemia. Further-
more, we found significant association of heterozygous
genotype (*1/*3) of CYP2C9*3 with grade 2-4 leucopenia
and CT genotype of NQO1 polymorphism with dose
delay/ reduction. However, none of the polymorphisms
were found to be statistically significant with grade 2-4
toxicity. On MDR analysis, ABCB1 1236C>T polymorph-
ism yielded the highest testing accuracy for response to
NACT (CVT=0.61, CVC= 10/10, p =0.0067). However,
ABCB1 1236C>T, ABCB1 2677G>T/A, CYP2C19*2 com-
bination of polymorphisms yielded the highest testing
accuracy for grade 2-4 anemia (CVT=0.66, CVC= 10/10,
p < 0.0001). Similarly, the above combination of
polymorphisms provided the best interaction model for
overall toxicity as well (CVT=0.65, CVC= 10/10, p <
0.0001). For dose delay/ reduction, NQO1 609 C>T poly-
morphism yielded the highest testing accuracy
(CVT=0.60, CVC= 9/10, p =0.0048). However, CYP2B6*9
polymorphism with the testing accuracy (CVT=0.43,
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CVC= 5/10) for grade 2-4 leucopenia did not achieve sta-
tistical significance (p= 0.1088).
Conclusions
Multi-analytical approaches may provide a better predic-
tion of pharmacogenetic based clinical outcomes in
breast cancer patients.
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